



Express Mail No.: EV 335 859 795 US

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Zhengming CHEN et al.	Confirmation No.:	5169
Serial No.:	10/669,875	Art Unit:	1614
Filed:	September 23, 2003	Examiner:	To Be Assigned
Title:	THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN	Attorney Docket No.:	6750-195-999 (CAM No.: 305158-999193)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the above-identified U.S. patent application. It is requested that the Examiner make this information of record in the examination of the application.

Enclosures accompanying this Information Disclosure Statement are:

1. A List of References Cited by Applicants (References **B01-B23**); and
2. A legible copy of References **B12-B23**, including English language abstracts of the non-English language publications; and all other information or portion that caused it to be listed on the List of References Cited by Applicants.

Since this application was filed on September 23, 2003, in accordance with 1276 OG 55, this Information Disclosure Statement is filed without copies of References **B1-B11**, which are U.S. patents and published applications in U.S. patent applications.

This Information Disclosure Statement supplements the Information Disclosure Statement filed on April 5, 2004 for the above-identified U.S. patent application.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of the first Office action on the merits. Therefore, no fee is believed to be due for this Information Disclosure Statement. Should the U.S. Patent and Trademark Office determine otherwise, the

Commissioner is authorized to charge any required fee to Jones Day Deposit Account No. 503013.

No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than the PCT International Search Report submitted herewith). 37.C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date: April 28, 2004

Samuel B. Abrams by
George A. Smith 42,140
30,605

Samuel B. Abrams (Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosures



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.

6750-195-999

(CAM: 305158-999193)

APPLICATION NO.

10/669,875

APPLICANT

Zhengming CHEN et al.

FILING DATE

September 23, 2003

GROUP

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B01	5,015,642	05-14-91	Lerch et al.			
	B02	5,025,010	06-18-91	Oekonomopulos et al.			
	B03	5,081,113	01-14-92	Claussner et al.			
	B04	5,108,996	04-28-92	Claussner et al.			
	B05	5,130,315	07-14-92	Ong et al.			
	B06	5,143,923	09-01-92	Hrib et al.			
	B07	5,473,072	12-05-95	Mezei et al.			
	B08	5,478,823	12-26-95	Shibayama et al.			
	B09	5,486,517	01-23-96	Downing et al.			
	B10	6,346,622	02-12-02	Lubisch et al.			
	B11	6,414,157	07-02-02	Lubisch et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B12	JP 63-010760	01-18-88	Japan (w/ English Abstract)			X	
	B13	GB 2 201 417 A	09-01-88	United Kingdom				
	B14	DE 3714371 A1	11-10-88	Germany (w/ English Abstract)			X	
	B15	WO 98/15546	04-16-98	PCT				
	B16	WO 00/41697	07-20-00	PCT (w/ English Abstract)			X	
	B17	Int. Search Report of PCT/US 03/30187	02-16-04	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	B18	Abramets et al., "Serotonergic and Dopaminergic Mechanisms of the Action of 1-Pyrimidinylpiperazine Derivatives," <i>Eksp. Klin. Farmakol.</i> 55(3):8-11 (1992) (original text in Russian w/ English Abstract)						
	B19	Dianov et al., "Synthesis and Immunotropic Activity of Thiazole [3,2-A] Benzimidazole Derivatives," <i>Khimiko-Farmatsevticheskii Zhurnal</i> 25(1):40-41 (1991) (original text in Russian w/ English Abstract)						

	B20	Ishizumi et al., "Synthesis and Anxiolytic Activity of <i>N</i> -Substituted Cyclic Imides (1 <i>R</i> *,2 <i>S</i> *,3 <i>R</i> *,4 <i>S</i> *)- <i>N</i> -[4-[4-(2-Pyrimidinyl)-1-piperazinyl]butyl]-2,3-bicyclo[2.2.1]heptanedicarboximide (Tandospirone) and Related Compounds," <i>Chem. Pharm. Bull.</i> 39 (9):2288-2300 (1991)
	B21	Kartal et al., "Liquid Chromatographic Method for the Analysis of Buspirone HCl and Its Potential Impurities," <i>Journal of Chromatographic Science</i> 38 :151-156 (2000)
	B22	Naletov et al., "Analysis of Structure-Antiemetic Activity Relations of Piperazinylalkyl Derivatives of Cyclic Imides," <i>Khimiko-Farmatsevticheskii Zhurnal</i> 31 (9):35-40 (1997) (original text in Russian w/ English Abstract)
	B23	Welch et al., "A General Synthetic Method Suitable for the Introduction of Deuterium or Tritium in Buspirone Type Anxiolytic Agents," <i>Journal of Labelled Compound and Radiopharmaceuticals</i> 27 (6):701-706 (1988)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.